HK Stock Market Move | CSTONE PHARMA-B (02616) saw another increase of over 5%, GIC recently increased its stake in the company, and strategic cooperation continues to be implemented.

CSTONE PHARMA-B(02616) rose by over 5%, hitting 4.8% as of the time of publication, reaching 10.7 Hong Kong dollars, with a trading volume of 3.01 billion Hong Kong dollars. On the news front, according to documents disclosed by the Hong Kong Stock Exchange on August 20, on August 18, the Singapore government investment company (GIC) increased its stake in CStone Pharma by 80.4 million common shares, at an average price of 7.9 Hong Kong dollars per share, with a total value of about 635 million Hong Kong dollars. After the increase, GIC's latest stake in CStone Pharma rose from 0.00% to 5.49%. It is worth noting that the company's strategic partnerships continue to be implemented. Southwest stated that in March 2025, SUGIROMAB was submitted to the European Medicines Agency (EMA) for a new indication application for the treatment of unresectable stage III NSCLC patients who have not experienced disease progression after synchronous or sequential radiotherapy and chemotherapy. In January 2025, the company reached a commercial strategic partnership with SteinCares for 10 Latin American countries, and in July 2025, they reached a strategic partnership with Gentili for 23 countries in Western Europe and the United Kingdom. Currently, the international influence of SUGIRIMAB has expanded to more than 60 countries worldwide.